randomised controlled trial

随机受控试验
  • 文章类型: Journal Article
    目的:潜在有害的多重用药是一个日益增长的公共卫生问题。本文旨在评估结构化团队方法来评估和减少多药房(AusTAPER)框架的有效性。
    方法:我们招募了大城市医院的患者进行一项随机对照试验,随访12个月。干预措施包括全面的药物史,多学科会议和出院前的药物审查,出院后与参与者的全科医生接触。主要结果是与基线相比12个月时使用的常规药物数量的变化。进行成本结果以估计研究期间每个参与者的成本。
    结果:有98名参与者参加了这项研究。两组常规药物的数量均较基线显着减少(对照组为-1.7±4.3,t=2.38,P=0.02,对照组为-2.7±3.6,t=4.48,P=0.0001),尽管两组之间没有统计学差异(1.0(SE0.9),t=1.03,P=0.31)。该干预措施估计费用为644.17澳元,并与每位参与者持续降低药物成本的成本节省552.53澳元相关。两组的健康结果和医疗费用相似。
    结论:两组药物均显著减少,干预组的药物在12个月时有更大的减少趋势。干预成本大约被持续降低的药品成本所抵消,尽管这些结果应谨慎考虑,因为组间结局差异无显著性.
    OBJECTIVE: Potentially harmful polypharmacy is a growing public health concern. This article aims to evaluate the effectiveness of a structured Team Approach to Polypharmacy Evaluation and Reduction (AusTAPER) framework.
    METHODS: We recruited patients at metropolitan hospitals for a randomised controlled trial with 12 months of follow-up. The intervention included a comprehensive medicines history, multidisciplinary meeting and medicines review prior to discharge, with engagement with the participants\' general practitioner extending after discharge. The primary outcome was the change in the number of regular medicines used at 12 months from baseline. A cost consequence was performed to estimate costs per participant during the study period.
    RESULTS: There were 98 participants enrolled in the study. The number of regular medicines was significantly reduced from baseline in both groups (-1.7 ± 4.3, t = 2.38, P = 0.02 in the control group vs -2.7 ± 3.6, t = 4.48, P = 0.0001 in the intervention group), although there was no statistical difference detected between the two groups (1.0 (SE 0.9), t = 1.03, P = 0.31). The intervention was estimated to cost AU$644.17 and was associated with cost savings of AU$552.53 per participant in sustained reduced medicines cost. Health outcomes and healthcare costs were similar in both groups.
    CONCLUSIONS: Medicines were significantly reduced in both groups, with a trend to a larger reduction in medicines at 12 months in the intervention group. The intervention cost was approximately offset by sustained reduced medicines cost, although these results should be regarded cautiously because of the absence of significance in the differences in outcomes between groups.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:磷酸肌醇3-激酶(PI3K)抑制剂可与标准疗法一起用于癌症进展和死亡率,以提高晚期乳腺癌(ABC)的治疗效果。
    目的:本系统综述和Meta分析旨在了解PI3K抑制剂在ABC中的治疗和毒性概况。
    方法:根据标准搜索电子数据库以寻找合适的试验。评估的结果是无进展生存期,客观反应率和疾病控制率。采用Mantele-Haenszel方法对数据进行系统回顾和荟萃分析。
    结果:7项研究纳入系统综述和Meta分析。PI3K抑制剂与标准疗法的共同给药显著改善了无进展生存率,虽然观察到客观反应率略有改善,疾病控制率和毒性无显著增加差异。
    结论:添加PI3K抑制剂降低了进展风险,但增加了毒性风险。
    BACKGROUND: The Phosphoinositide 3-kinase (PI3K) inhibitors may be used in cancer progression and mortality along with standard therapy to improve therapeutic efficacy of Advanced Breast Cancer (ABC).
    OBJECTIVE: This systematic review and meta- analysis were conducted to understand the therapeutic and toxicity profile of PI3K inhibitors in ABC.
    METHODS: The electronic databases were searched for suitable trials as per the criteria. The outcomes assessed were Progression- Free Survival, Objective Response Rate and Disease Control Rate. The data were systematically reviewed and meta-analyzed by Mantele- Haenszel method.
    RESULTS: Seven studies were included in the systematic review and meta- analysis. The co- administration of PI3K inhibitors with standard therapy improved the Progression- Free Survival significantly, while a marginal improvement was observed in Objective Response Rate, no difference in Disease Control Rate and toxicity significantly increased.
    CONCLUSIONS: The addition of PI3K inhibitors decreased the risk of progression but increased the risk of toxicity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    血管通路装置对急诊科(ED)患者的重要性是不可否认的。在评估干预措施的有效性时,与其他研究设计相比,随机对照试验(RCT)是最可靠的证据来源.
    探索和综合ED设置中与血管通路装置相关的RCT的发现。
    将在包括Cochrane中央对照试验登记册在内的电子医疗数据库中进行系统搜索,Pubmed,CINAHL和Embase数据库。所有RCT都集中在外周静脉导管上,中心静脉导管和骨内导管,在过去的十年里,在同行评审期刊上以中英文发表,将包括在内。
    本范围审查将总结ED设置中血管通路装置的当前证据状态。这将确定文献中的差距,反过来,协助临床医生和研究人员确定未来探索的领域,并为未来的研究提供有价值的指导。
    UNASSIGNED: The significance of vascular access devices for patients in the emergency department (ED) is undeniable. When it comes to evaluating the effectiveness of interventions, randomised controlled trials (RCTs) stand out as the most reliable sources of evidence compared with other study designs.
    UNASSIGNED: To explore and synthesise the findings from RCTs related to vascular access devices in the ED setting.
    UNASSIGNED: A systematic search will be conducted in electronic medical databases including the Cochrane Central Register of Controlled Trials, Pubmed, CINAHL and Embase databases. All RCTs focusing on peripheral intravenous catheters, central venous catheters and intraosseous catheters, published in English and Chinese in peer-reviewed journals within the past decade, will be included.
    UNASSIGNED: This scoping review will summarise the current state of evidence for vascular access devices in the ED setting. This will identify gaps in the literature and, in turn, assist clinicians and researchers in pinpointing areas for future exploration and provide a valuable guide for future research.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:药剂师主导的药物审查是一种既定的干预措施,以支持患者处方多种药物或复杂的药物治疗方案。对于这项系统审查,药物审查被定义为“药剂师和患者之间的咨询,以审查患者的总药物使用情况,以期改善患者的健康状况并最大限度地减少与药物相关的问题”。目前尚不清楚药物审查的不同方法如何导致不同的结果。
    目的:从药剂师主导的药物综述中探讨与积极结果相关的共同主题。
    方法:纳入18岁及以上成人药剂师主导药物综述的随机对照试验。MEDLINE中使用的搜索词,EMBASE和WebofScience数据库是“药物审查”,\"药剂师\",“随机对照试验”及其同义词,时间过滤器2015年至2023年9月。2015年之前发表的研究是从先前的系统评价中确定的。使用Cochrane偏倚风险2工具评估偏倚风险。药物评价的描述\'组件,对实施和成果进行了叙述综合,以得出共同的主题。结果呈现在表中。
    结果:68篇描述50项研究的论文符合纳入标准。综合产生的共同主题包括协作工作,这可能有助于减少药物相关问题和处方药物的数量;患者参与目标设定和行动计划,这可能会提高患者按照处方服用药物并帮助他们实现治疗目标的能力;额外的支持和后续行动,这可能会导致血压的改善,糖尿病控制,生活质量和减少药物相关问题。
    结论:本系统综述确定了共同的主题和组成部分,例如,目标设定,行动计划,额外的支持和后续行动,这可能会影响药剂师主导的药物审查的结果。研究人员,卫生专业人员和专员可以使用这些数据对药物审查实施情况进行全面评估.
    CRD42020173907。
    BACKGROUND: Pharmacist-led medication reviews are an established intervention to support patients prescribed multiple medicines or with complex medication regimes. For this systematic review, a medication review was defined as \'a consultation between a pharmacist and a patient to review the patient\'s total medicines use with a view to improve patient health outcomes and minimise medicines-related problems\'. It is not known how varying approaches to medication reviews lead to different outcomes.
    OBJECTIVE: To explore the common themes associated with positive outcomes from pharmacist-led medication reviews.
    METHODS: Randomised controlled trials of pharmacist-led medication reviews in adults aged 18 years and over were included. The search terms used in MEDLINE, EMBASE and Web of Science databases were \"medication review\", \"pharmacist\", \"randomised controlled trial\" and their synonyms, time filter 2015 to September 2023. Studies published before 2015 were identified from a previous systematic review. Risk of bias was assessed using the Cochrane risk of bias 2 tool. Descriptions of medication reviews\' components, implementation and outcomes were narratively synthesised to draw out common themes. Results are presented in tables.
    RESULTS: Sixty-eight papers describing 50 studies met the inclusion criteria. Common themes that emerged from synthesis include collaborative working which may help reduce medicines-related problems and the number of medicines prescribed; patient involvement in goal setting and action planning which may improve patients\' ability to take medicines as prescribed and help them achieve their treatment goals; additional support and follow-up, which may lead to improved blood pressure, diabetes control, quality of life and a reduction of medicines-related problems.
    CONCLUSIONS: This systematic review identified common themes and components, for example, goal setting, action planning, additional support and follow-up, that may influence outcomes of pharmacist-led medication reviews. Researchers, health professionals and commissioners could use these for a comprehensive evaluation of medication review implementation.
    UNASSIGNED: CRD42020173907.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:尽管通过旨在降低术后谵妄发生率的随机试验进行了大量研究,但术后谵妄仍然普遍存在。了解与干预措施有效性相关的试验特征有助于数据解释。
    方法:从通过两个系统文献检索确定的合格试验中提取试验特征。多变量meta回归用于研究与使用比值比估计的有效性相关的试验特征。Meta分析用于调查综合有效性。
    结果:我们确定了201项符合条件的试验。与中国相比,来自美国/加拿大的试验(比值比,1.89;95%置信区间,1.45-2.45)和欧洲/澳大利亚/新西兰(1.67;1.29-2.18)的赔率比分别高出89%和67%,分别,表明有效性降低。当术后谵妄的发生率增加(0.85;0.79-0.92,每增加10%)时,有效性增强。与预期干预措施的偏差相关的关注试验报告与低风险试验相比,有效性提高(0.69;0.53-0.90)。与平时护理相比,在低风险试验中,某些干预措施似乎降低了术后谵妄的发生率,证据确定性为低至中度.然而,这些发现应该被认为是不确定的,因为在分组异质干预措施方面存在挑战,符合条件的审判数量有限,小规模研究的普遍性,和潜在的出版偏见。
    结论:术后谵妄试验的有效性因试验来源地区而异,谵妄的发生率,以及偏见的风险。这些限制警告不要从不同的证据中得出明确的结论。这些发现凸显了在全球范围内提高研究质量的迫切需要。
    PROSPERO(CRD42023413984)。
    BACKGROUND: Postoperative delirium remains prevalent despite extensive research through randomised trials aimed at reducing its incidence. Understanding trial characteristics associated with interventions\' effectiveness facilitates data interpretation.
    METHODS: Trial characteristics were extracted from eligible trials identified through two systematic literature searches. Multivariable meta-regression was used to investigate trial characteristics associated with effectiveness estimated using odds ratios. Meta-analysis was used to investigate pooled effectiveness.
    RESULTS: We identified 201 eligible trials. Compared with China, trials from the USA/Canada (ratio of odds ratio, 1.89; 95% confidence interval, 1.45-2.45) and Europe/Australia/New Zealand (1.67; 1.29-2.18) had an 89% and 67% higher odds ratio, respectively, suggesting reduced effectiveness. The effectiveness was enhanced when the incidence of postoperative delirium increased (0.85; 0.79-0.92, per 10% increase). Trials with concerns related to deviations from intended interventions reported increased effectiveness compared with those at low risk (0.69; 0.53-0.90). Compared with usual care, certain interventions appeared to have reduced the incidence of postoperative delirium in low-risk trials with low-to-moderate certainty of evidence. However, these findings should be considered inconclusive because of challenges in grouping heterogeneous interventions, the limited number of eligible trials, the prevalence of small-scale studies, and potential publication bias.
    CONCLUSIONS: The effectiveness of postoperative delirium trials varied based on the region of trial origin, the incidence of delirium, and the risk of bias. The limitations caution against drawing definitive conclusions from different bodies of evidence. These findings highlight the imperative need to improve the quality of research on a global scale.
    UNASSIGNED: PROSPERO (CRD42023413984).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    本系统评价旨在研究非药物干预措施对改善患有神经系统疾病的女性护理人员的心理健康结果的有效性。
    对英语随机对照试验进行叙述性综合。
    包括18项独特的研究。发现改善心理健康结果的干预成分是:亲自交付,对团体来说,间歇性安排,治疗时间≥10次;持续时间在3-6个月之间;并得到研究人员或专职医疗专业人员的协助.由于这篇综述很少有强有力的研究,本综述重点介绍了被评估为低偏倚风险的研究中报告的心理健康结局结果.心理教育干预,认知行为干预,发现支持小组干预措施可以改善抑郁症。还发现心理教育干预措施可以改善负担。
    显然需要足够的动力,高质量的随机对照试验,以确定非药物干预对患有神经系统疾病的女性护理人员的有效性。
    与男性护理者相比,女性护理者的心理健康和幸福感较差,并且患慢性健康问题的风险更高。这次审查只确定了很少,一般较小,非药物干预在女性护理人员神经系统疾病患者中的随机对照试验。提供心理教育的干预措施,是基于群体的,面对面,干预持续时间在>3个月和<6个月之间,可能会成功改善一些心理健康结果,比如抑郁和应对。
    UNASSIGNED: This systematic review aims to examine the effectiveness of non-pharmacological interventions for improving mental health outcomes among female carers of people living with a neurological condition.
    UNASSIGNED: A narrative synthesis of English-language randomized controlled trials was undertaken.
    UNASSIGNED: 18 unique studies were included. Intervention components that were found to have improved mental health outcomes were: delivered in person, to groups, on an intermittent schedule with ≥10 sessions; had a duration between 3-6 months; and were facilitated by research staff or allied health professionals. As the review had few robust studies, results of mental health outcomes reported in studies assessed as low risk of bias were highlighted in the review. Psychoeducation interventions, cognitive behavioural interventions, and support group interventions were found to improve depression. Psychoeducation interventions were also found to improve burden.
    UNASSIGNED: There is a clear need for adequately powered, high-quality randomised controlled trials to determine the effectiveness of non-pharmacological interventions for female carers of people living with a neurological condition.
    Female carers experience worse mental health and well-being outcomes and are at a higher risk of developing chronic health issues compared to their male counterparts.This review identified only very few, generally small, randomised controlled trials of non-pharmacological interventions in female carers of patients with neurological conditions.Interventions that provide psychoeducation, are group-based, face-to-face, and have an intervention duration between >3 months and <6 months, may be successful in improving some mental health outcomes, such as depression and coping.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    气管拔管常引起心血管和气道反应,可能导致危险后果。目前尚不清楚右美托咪定或利多卡因是否更有效抑制咳嗽。因此,我们对随机对照试验进行了系统评价和荟萃分析,以比较右美托咪定和利多卡因降低成人患者气管插管后咳嗽反应的有效性和安全性.
    彻底搜索电子数据库,包括PubMed,Embase,科克伦图书馆,和WebofScience,进行了相关研究(从开始到2023年1月31日)。纳入了随机对照试验,比较了全身麻醉下成年患者在麻醉苏醒期间静脉(IV)右美托咪定与静脉利多卡因给药预防气管拔管反应。主要结果是拔管后咳嗽的发生率。次要结果包括出现时间,拔管时间,残余镇静,和心动过缓的发生率。采用RevMan软件进行统计分析。使用Cochrane偏差风险工具评估潜在的偏差风险。
    总共,纳入了7项研究,共450名参与者.右美托咪定和利多卡因组咳嗽发生率无统计学差异[风险比=0.76;95%置信区间:0.46,1.24]。两组之间的出现和拔管时间没有显着差异。Meta分析显示,与利多卡因组相比,右美托咪定组的心动过缓和残留镇静的发生率更高。
    这项荟萃分析发现咳嗽没有差异,出现,右美托咪定和利多卡因气管拔管后的拔管时间。然而,右美托咪定的残余镇静和心动过缓比利多卡因更显著.
    UNASSIGNED: Tracheal extubation often causes cardiovascular and airway responses, potentially resulting in hazardous consequences. It remains unknown whether dexmedetomidine or lidocaine is more effective for cough suppression. Hence, we conducted a systematic review and meta-analysis of randomised controlled trials to compare the effectiveness and safety of dexmedetomidine and lidocaine in reducing cough response after tracheal extubation in adult patients.
    UNASSIGNED: A thorough search of electronic databases, including PubMed, Embase, Cochrane Library, and Web of Science, was conducted to identify relevant studies (from inception to 31 January 2023). Randomised controlled trials comparing intravenous (IV) dexmedetomidine versus IV lidocaine administration during emergence from anaesthesia to prevent tracheal extubation response in adult patients under general anaesthesia were included. The primary outcome was the incidence of post-extubation cough. Secondary outcomes included emergence time, extubation time, residual sedation, and incidences of bradycardia. Statistical analysis was conducted using RevMan software. The Cochrane risk of bias tool was used to evaluate the potential risk for bias.
    UNASSIGNED: In total, seven studies with 450 participants were included. There was no statistically significant difference in the incidence of cough between dexmedetomidine and lidocaine groups [Risk Ratio = 0.76; 95% Confidence Interval: 0.46, 1.24]. Emergence and extubation times were not significantly different between the two groups. Meta-analysis revealed a higher incidence of bradycardia and residual sedation in dexmedetomidine compared to the lidocaine group.
    UNASSIGNED: This meta-analysis found no difference in cough, emergence, and extubation time between dexmedetomidine and lidocaine after tracheal extubation. However, residual sedation and bradycardia were more significant in dexmedetomidine than in lidocaine.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Meta-Analysis
    背景:代谢功能障碍相关的脂肪性肝病(MASLD)是慢性肝病的常见原因。这篇综述评估了低热量饮食(LCD)对MASLD和肥胖症患者肝脏健康和体重的影响。
    方法:该研究已在PROSPERO(CRD42021296501)注册,并使用多个数据库进行文献检索.关键的纳入标准是随机对照试验或队列研究,肥胖/超重和体格。两位作者筛选了摘要,查看全文,并进行数据提取和质量评估。主要结果是血清ALT的变化,次要结果包括血清AST的变化,肝内脂质含量(IHL),通过MRI/MRS无创定量,和体重。
    结果:共纳入15项研究。与对照组相比,LCD降低了9.1kg的体重(95CI:-12.4,-5.8),但没有血清ALT(-5.9IU/L,-13.9、2.0)。总膳食替代(TDR)使IHL减少-9.1%对照(-15.6%,-2.6%)。地中海LCD≥12个月降低ALT(-4.1IU/L,-7.6,-0.5),与其他LCD相比,24个月的肝脏硬度降低。绿色地中海LCD减少了IHL,独立于体重。有限的研究评估了黑人或亚洲种族,并且在评估肝脏脂肪含量和纤维化的方法中存在异质性。
    结论:在患有MASLD和肥胖症的人群中,LCD干预可降低IHL和体重。审判应侧重于招募黑人和亚洲族裔参与者。
    BACKGROUND: Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) is a common cause of chronic liver disease. This review assessed the efficacy of a Low-Calorie Diet (LCD) on liver health and body weight in people living with MASLD and obesity.
    METHODS: The study was registered with PROSPERO (CRD42021296501), and a literature search was conducted using multiple databases. The key inclusion criteria were randomised controlled trials or cohort studies, obesity/overweight and MASLD. Two authors screened abstracts, reviewed full texts and performed data extraction and quality assessment. The primary outcome was the change in the serum ALT, and secondary outcomes included the changes in the serum AST, intrahepatic lipid content (IHL), quantified non-invasively via MRI/MRS, and body weight.
    RESULTS: Fifteen studies were included. The LCD reduced body weight by 9.1 kg versus the control (95%CI: -12.4, -5.8) but not serum ALT (-5.9 IU/L, -13.9, 2.0). Total Dietary Replacement (TDR) reduced IHL by -9.1% vs. the control (-15.6%, -2.6%). The Mediterranean-LCD for ≥12 months reduced ALT (-4.1 IU/L, -7.6, -0.5) and for 24 months reduced liver stiffness versus other LCDs. The Green-Mediterranean-LCD reduced IHL, independent of body weight. Limited studies assessed those of Black or Asian ethnicity, and there was heterogeneity in the methods assessing the liver fat content and fibrosis.
    CONCLUSIONS: In people with MASLD and obesity, an LCD intervention reduces IHL and body weight. Trials should focus on the recruitment of Black and Asian ethnicity participants.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在一系列随机对照试验(RCT)中发现了间歇性禁食(IF)对健康相关结局的益处。我们的总括审查旨在系统分析和综合有关IF的现有因果证据及其对特定健康相关结果的影响,同时评估其证据质量。
    我们全面搜索了PubMed,Embase,WebofScience,和Cochrane数据库(从开始到2024年1月8日),以确定相关的系统评价和荟萃分析RCT调查IF和人类健康结局之间的关联。我们将每个荟萃分析的效应大小重新计算为平均差(MD)或标准化平均差(SMD)以及相应的95%置信区间(CI)。根据三种特定状态对人群进行了亚组分析:糖尿病,超重或肥胖,和代谢综合征。使用评估系统评价的测量工具(AMSTAR)评估系统评价的质量,证据的确定性是使用建议分级来评估的,评估,发展,和评估(等级)系统。本研究在PROSPERO(CRD42023382004)注册。
    来自23个meta分析和34个健康结局的共351个关联被纳入研究。调查了广泛的结果,包括人体测量(n=155),血脂谱(n=83),血糖分布(n=57),循环系统指数(n=41),食欲(n=9),和其他人(n=6)。根据AMSTAR标准,有346个关联的21个(91%)荟萃分析被评为高置信度。在103个关联中,汇总效应估计值在p<0.05处显着,其中10人(10%)根据等级得到了高确定性证据的支持。具体来说,与超重或肥胖成人的非干预饮食相比,如果腰围减少(WC)(MD=-1.02cm;95%CI:-1.99至-0.06;p=0.038),脂肪质量(MD=-0.72kg;95%CI:-1.32至-0.12;p=0.019),空腹胰岛素(SMD=-0.21;95%CI:-0.40至-0.02;p=0.030),低密度脂蛋白胆固醇(LDL-C)(SMD=-0.20;95%CI:-0.38至-0.02;p=0.027),总胆固醇(TC)(SMD=-0.29;95%CI:-0.48至-0.10;p=0.003),和三酰基甘油(TG)(SMD=-0.23;95%CI:-0.39至-0.06;p=0.007),但无脂肪质量(FFM)增加(MD=0.98kg;95%CI:0.18-1.78;p=0.016)。值得注意的是,与非干预饮食相比,改良隔日禁食(MADF)可降低脂肪量(MD=-0.70kg;95%CI:-1.38至-0.02;p=0.044)。超重或肥胖的人,和2型糖尿病,与连续能量限制(CER)相比,IF会增加高密度脂蛋白胆固醇(HDL-C)水平(MD=0.03mmol/L;95%CI:0.01-0.05;p=0.010)。然而,在超重或肥胖的成年人中,IF在降低收缩压(SBP)方面的效果不如CER饮食(SMD=0.21;95%CI:0.05-0.36;p=0.008)。
    我们的研究结果表明,如果对超重或肥胖的成年人的一系列健康结果可能有有益的影响,与CER或非干预饮食相比。具体来说,如果可能会降低WC,脂肪量,LDL-C,TG,TC,空腹胰岛素,和SBP,同时增加HDL-C和FFM。值得注意的是,值得注意的是,IF降低SBP的作用似乎弱于CER。
    这项工作得到了国家重点研究发展计划(Q-JW)的支持,中国自然科学基金(Q-JW和T-TG),中国医科大学附属盛京医院优秀科学基金(Q-JW),中国医科大学附属盛京医院(T-TG)345人才项目。
    UNASSIGNED: Benefits of Intermittent fasting (IF) on health-related outcomes have been found in a range of randomised controlled trials (RCTs). Our umbrella review aimed to systematically analyze and synthesize the available causal evidence on IF and its impact on specific health-related outcomes while evaluating its evidence quality.
    UNASSIGNED: We comprehensively searched the PubMed, Embase, Web of Science, and Cochrane databases (from inception up to 8 January 2024) to identify related systematic reviews and meta-analyses of RCTs investigating the association between IF and human health outcomes. We recalculated the effect sizes for each meta-analysis as mean difference (MD) or standardized mean difference (SMD) with corresponding 95% confidence intervals (CIs). Subgroup analyses were performed for populations based on three specific status: diabetes, overweight or obesity, and metabolic syndrome. The quality of systematic reviews was evaluated using A Measurement Tool to Assess Systematic Reviews (AMSTAR), and the certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) system. This study is registered with PROSPERO (CRD42023382004).
    UNASSIGNED: A total of 351 associations from 23 meta-analyses with 34 health outcomes were included in the study. A wide range of outcomes were investigated, including anthropometric measures (n = 155), lipid profiles (n = 83), glycemic profiles (n = 57), circulatory system index (n = 41), appetite (n = 9), and others (n = 6). Twenty-one (91%) meta-analyses with 346 associations were rated as high confidence according to the AMSTAR criteria. The summary effects estimates were significant at p < 0.05 in 103 associations, of which 10 (10%) were supported by high certainty of evidence according to GRADE. Specifically, compared with non-intervention diet in adults with overweight or obesity, IF reduced waist circumference (WC) (MD = -1.02 cm; 95% CI: -1.99 to -0.06; p = 0.038), fat mass (MD = -0.72 kg; 95% CI: -1.32 to -0.12; p = 0.019), fasting insulin (SMD = -0.21; 95% CI: -0.40 to -0.02; p = 0.030), low-density lipoprotein cholesterol (LDL-C) (SMD = -0.20; 95% CI: -0.38 to -0.02; p = 0.027), total cholesterol (TC) (SMD = -0.29; 95% CI: -0.48 to -0.10; p = 0.003), and triacylglycerols (TG) (SMD = -0.23; 95% CI: -0.39 to -0.06; p = 0.007), but increased fat free mass (FFM) (MD = 0.98 kg; 95% CI: 0.18-1.78; p = 0.016). Of note, compared with the non-intervention diet, modified alternate-day fasting (MADF) reduced fat mass (MD = -0.70 kg; 95% CI: -1.38 to -0.02; p = 0.044). In people with overweight or obesity, and type 2 diabetes, IF increases high-density lipoprotein cholesterol (HDL-C) levels compared to continuous energy restriction (CER) (MD = 0.03 mmol/L; 95% CI: 0.01-0.05; p = 0.010). However, IF was less effective at reducing systolic blood pressure (SBP) than a CER diet in adults with overweight or obesity (SMD = 0.21; 95% CI: 0.05-0.36; p = 0.008).
    UNASSIGNED: Our findings suggest that IF may have beneficial effects on a range of health outcomes for adults with overweight or obesity, compared to CER or non-intervention diet. Specifically, IF may decreased WC, fat mass, LDL-C, TG, TC, fasting insulin, and SBP, while increasing HDL-C and FFM. Notably, it is worth noting that the SBP lowering effect of IF appears to be weaker than that of CER.
    UNASSIGNED: This work was supported by the National Key Research and Development Program of China (Q-JW), the Natural Science Foundation of China (Q-JW and T-TG), Outstanding Scientific Fund of Shengjing Hospital of China Medical University (Q-JW), and 345 Talent Project of Shengjing Hospital of China Medical University (T-TG).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号